News

The College of Pharmacy  will host its 11th annual Therapeutics, Outcomes, Discovery & Delivery (TODD) Symposium from 8 a.m.–5 p.m. April 12, at the Lee T. Todd, Jr. Building.

Based within the UK College of Medicine’s Center on Drug and Alcohol Research, the UK Cannabis Center will build upon research already taking place at UK.

"While approved vaccines are able to prevent a COVID reinfection with a high effectiveness rate, it is still early on and we don't know how durable they are going to be in the long run. We also don’t know how effective these vaccines are at preventing asymptomatic spread. These questions are what researchers in my field will be looking at for many years to come."

Vince Venditto, PhD, assistant professor in the UK College of Pharmacy’s Department of Pharmaceutical Science, has extensive expertise in vaccine design. He was trained in organic synthesis and vaccine development. He is currently working on a clinical trial with community pharmacies to understand the prevalence of SARS-CoV-2 in Kentucky.

In our third and final part of this interview, we ask Vince and Brooke about how this pandemic possibly ends, and how we progress into a new world after COVID-19.

It has been nearly one year since the SARS-CoV-2 coronavirus changed the world. With millions of people infected and over a quarter-million dead in the United States, the novel coronavirus continues its pervasive hold on our health and well-being.

It has been nearly one year since SARS-COV-2 (COVID-19) changed the world. With millions of people infected and over a quarter-million dead in the United States (U.S.), the novel coronavirus continues its pervasive hold on our health and well-being.

Building on these findings, Plattner and Markey oncologists are now collaborating with the pharmaceutical company Novartis to develop a Phase I clinical trial to test the safety and effectiveness of using nilotinib in relapsed melanoma patients.

"We need stronger and more united NMR capabilities at UK and securing funding for this new state-of-the-art NMR instrument is a first step toward achieving this important goal," Garneau-Tsodikova said.

PDS0203 stands out among COVID-19 vaccines currently in development because it includes a vaccine technology pioneered by PDS Biotech called Versamune®, which stimulates important parts of the immune system to activate T cells.